AED 226.7 million the total profit of Julphar for the first quarter


Julphar announced unified sales revenue for the first quarter of this year worth AED 397.6 million, with a growth of 1.1% compared to the same period of 2014. The company’s financial results, which were shared within the Board of Director’s report, showed a total profit of AED 226.7 million and a decline of 4%.

The results showed a net profit of AED 60.3 million, registering a decline of 14%, the Board of Directors attributed the adverse profit growth during the first quarter of 2015 period due to low investment income. Julphar, unprecedented in the Middle East produces crude insulin using crystals derived from recombinant DNA technology, a state of the art facility that consists of 11 plants at its headquarters in Ras Al Khaimah, as it produces 213 products in different dosage forms and therapeutic areas that are distributed in over 40 countries.

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, refer to our Cookie Policy.